TNF and juvenile idiopathic arthritis: The first-line disease-modifying anti-rheumatic drug (DMARD) for treatment of JIA is usually methotrexate (MTX), followed or supplemented by anti-tumor necrosis factor alpha (anti-TNF-α) drugs, a group of the so-called biological DMARDs (bDMARDs).